Q3 2024 Repligen Corp Earnings Call Transcript
Key Points
- Repligen Corp (RGEN) reported a strong third quarter with a 10% year-over-year sales growth and a 6% increase in orders.
- The company's CDMO business rebounded to its highest revenue level in the last 18 months, indicating overall industry health.
- Repligen Corp (RGEN) achieved record revenue for new modalities, tracking to the highest annual revenue and order intake to date.
- The filtration franchise led in revenue growth, and chromatography saw an exceptional quarter for orders, up 35% year-over-year.
- Repligen Corp (RGEN) opened a new Training and Innovation Center, enhancing customer engagement and support.
- China remains a significant headwind, contributing only about 4% of 2024 revenues, with a 50% year-over-year decline in Q3.
- Emerging biotech showed weakness in Q3, with concerns over funding and clinical trial starts impacting performance.
- The company faces a $60 million to $65 million headwind from protein-related sales, impacting overall growth.
- Equipment orders have been slower to recover, although the funnel is strong, indicating potential future challenges.
- Repligen Corp (RGEN) is still finalizing required amendments for impacted financial statements due to a restatement.
Good day, ladies and gentlemen, and welcome to Repligen Corporation's third-quarter of 2024 earnings conference call. My name is Chad, and I will be your coordinator. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to Sondra Newman, Head of Investor Relations. Please go ahead.
Thank you, and welcome to our third quarter of 2024 report. On this call, we will cover business highlights and financial performance for the three- and nine-month periods ending September 30, 2024, and we'll provide financial guidance for the full year 2024. Joining us on the call today are Repligen's President and Chief Executive Officer, Olivier Loeillot; and our Chief Financial Officer, Jason Garland. As a reminder, the forward-looking statements that we make during the call, including those regarding our business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that may cause actual events or results to differ.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
